Wet Macular Degeneration Clinical Trial
Official title:
Phase IV Study to Evaluate the Efficacy of Aflibercept in Subjects With Neovascular Age-related Macular Degeneration (wAMD), Without Optimal Response to Repeated Monthly Intravitreal Injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy.
Patients with neovascular age-related macular degeneration who do not respond to usual treatment with conventional medications may respond to a new drug of the same class which is designed to block a larger fraction of proangiogenic factors.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04049266 -
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
|
Phase 2/Phase 3 | |
| Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
| Terminated |
NCT05038371 -
Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration
|
||
| Completed |
NCT03278262 -
The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting
|
||
| Completed |
NCT04982484 -
Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment
|
||
| Completed |
NCT00590694 -
Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
|
Phase 2/Phase 3 | |
| Completed |
NCT04516278 -
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
|
Phase 3 | |
| Completed |
NCT03844074 -
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
|
Phase 3 | |
| Recruiting |
NCT05637255 -
A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
|
Phase 2 | |
| Completed |
NCT04756310 -
Study of Nutritional Supplementation in Patients With Unilateral Wet AMD
|
N/A | |
| Active, not recruiting |
NCT05112861 -
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
|
Phase 3 | |
| Enrolling by invitation |
NCT03999801 -
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
|
Phase 2 | |
| Terminated |
NCT03699618 -
Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration
|
||
| Completed |
NCT01666821 -
A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population
|
N/A | |
| Completed |
NCT03022292 -
The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy
|
Phase 4 | |
| Completed |
NCT02944227 -
Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
|
Phase 4 | |
| Terminated |
NCT03452527 -
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
|
Phase 2 | |
| Completed |
NCT01243086 -
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
|
Phase 2 | |
| Completed |
NCT03823300 -
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
|
Phase 3 | |
| Recruiting |
NCT04420923 -
Optimizing the Treatment Strategy for Age-related Macular Degeneration
|
N/A |